Transforming the Epigenome

We develop first-in-class therapeutics targeting epigenetic alterations to treat chronic and age-related disease.
199 Biotechnolgies 'infinity' logo.

About 199 Bio

199 Biotechnologies pioneers first-in-class therapies that target the epigenetic alterations induced by chronic diseases and the ageing process. Our innovative medicines reprogram cells to fight disease, repair damage, and restore functions lost with age. We aim to revolutionise the treatment of both chronic and age-related conditions by addressing the root causes of ageing.

The Aging Problem

Aging significantly increases the risk of diseases like cardiovascular disease, neurodegenerative disorders, and cancers, placing a heavy burden on global healthcare.
1.

Current Treatments Fall Short

Current chronic disease treatments focus on managing symptoms but do not target the underlying root cause mechanisms of aging, leaving patients vulnerable to disease progression and reduced quality of life.
2.

The Root Cause

The epigenome, a master regulator of gene expression, undergoes changes with age that drive the onset of auto-immune conditions, loss of resilience, reduced immune function, and susceptibility to age-related diseases.
3.

Lack of Epigenetic Therapies

Despite the critical role of the epigenome in aging and disease, there are currently no existing treatments that effectively target and modulate the cell epigenome to address the root cause of age-related conditions.
The rising cost and burden of care in the global healthcare system
2.1B
People that will be 60+ by 2050
10%
Global GDP spent on treatment costs
86%
Adults over 65 have at least 1 chronic disease
$37T
Value of a therapy that slows aging by just 1 year

Our approach

1.

Epigenetic Reprogramming

Our reprogramming technology erases both aging and disease-associated epigenetic alterations, restores youthful cellular function, and aims to treat chronic conditions at their source.
2.

Playground Approach

We combine bioengineering, AI, microfluidics, and genetics with a multi-disciplinary expert team to develop groundbreaking solutions for age-related diseases, enhancing our reach and fostering valuable collaborations.
3.

Impact Focus

Epigenetic reprogramming has up to 100x factor magnitude of effects in clinical applications, offering unparalleled potential across various conditions with its broad ranging effects.

Epigenetic Rejuvenation

Overview

Epigenetic rejuvenation, also known as partial cellular reprogramming, targets the fundamental biological processes that drive aging. This innovative approach aims to erase the disease and aging-associated epigenetic alterations, in the process restoring cells to their youthful and healthy phenotype.

High Impact

Epigenetic reprogramming has a profound impact due to its ability to reverse multiple hallmarks of aging, and do it on a profound way. By modulating the reprogramming machinery and pathways in cells, our therapies can rejuvenate cells without altering their identity. This precise control can lead to dramatic improvements in cellular function and tissue regeneration, offering transformative potential across various clinical applications. Our preclinical models have demonstrated effects unmatched by current drugs in regenerative capacity and functional restoration of tissues affected by age-related diseases, including neurodegenerative disorders, cardiovascular diseases, and cancer.

Broad Effects

Epigenetic rejuvenation impacts multiple hallmarks of aging, including:

  • Genomic Stability: Reduces DNA damage and enhances DNA repair mechanisms.
  • Proteostasis: Improves protein folding, reduces protein aggregation, and enhances autophagy.
  • Mitochondrial Function: Restores mitochondrial efficiency, reducing oxidative stress and improving energy production.
  • Cellular Senescence: Decreases the number of senescent cells, reducing chronic inflammation and promoting tissue regeneration.
  • Stem Cell Function: Enhances the function and proliferative capacity of stem cells, supporting tissue repair and regeneration.

Platforms

Our delivery strategy consists of mRNA delivery and cell therapy. Our mRNA platform is well-established, with ongoing experiments focused on optimizing delivery techniques for maximum efficacy. Similarly, our cell therapy platform uses viral vectors, honing in on yield optimization, better promoter usage, and improved tropism to enhance the delivery and effectiveness of our reprogramming therapies.

mRNA

Our mRNA platform leverages advanced delivery systems to introduce reprogramming factors directly into cells. This method ensures precise, controlled expression of factors necessary for epigenetic reprogramming without permanent genetic modifications. This approach allows for transient expression, minimizing the risk of oncogenic transformations while maximizing therapeutic benefits.

Cell Therapy

Our cell therapy platform utilizes viral vectors to deliver reprogramming factors into cells. By refining promoter usage and tropism, we ensure targeted delivery and efficient reprogramming, enhancing therapeutic outcomes for age-related diseases. In addition to their systemic effects, these vectors are designed to maximize gene transfer efficiency and specificity, reducing off-target effects and improving overall safety.

Ex-Vivo

Ex-vivo approaches involve reprogramming cells outside the body before reintroducing them to the patient. This method allows for precise control and monitoring of the reprogramming process, ensuring optimal cell function before transplantation. Ex-vivo reprogramming is particularly useful for generating patient-specific treatments with reduced risk of immune rejection.

Organ-on-a-Chip

Our organ-on-a-chip technology simulates human organ systems in vitro, providing a platform to study the effects of epigenetic rejuvenation in a controlled environment. This innovation accelerates our understanding and optimization of reprogramming therapies, enabling high-throughput screening and detailed mechanistic studies.

Pipeline

Indication
Drug
Progress
-
Cancer
EMX001
Pre-clinical / In-vivo
-
Cancer
EMX001
Pre-clinical
-
Neurology
EMX003
Pre-clinical / In-vivo
-
Cardiology
EMX004
Pre-IND
-
Dermatology
EMX005
Pre-clincal / In-vivo xenograft
-
Immunology
EMX002
In-vitro
-
Immunology
EMX002
In-vitro
-

Models for Aging & Disease

Introduction

Our models for aging and disease research leverage cutting-edge technologies to study and combat age-related conditions at their core. By mimicking the complexity of human systems, we aim to provide accurate insights and develop effective therapies.

Micro-vasculature

Our microvasculature models enable the study of vascular aging and related diseases by replicating the intricate network of blood vessels. These models allow us to observe how different interventions affects vascular health and function. For example, our studies show that fibroblasts from old donors cannot form vasculature, but epigenetic reprogramming can restore youthful phenotype, restoring their ability to form functional blood vessels.

Myelination

Our myelination models focus on the health of the nervous system, particularly the insulation of nerve fibres. By studying these models, we aim to understand and reverse the decline in neural function associated with aging. Through advanced in vitro models that replicate the size and texture of neurons, we can observe the processes of myelin formation and degradation. Our methods include using 3D hydrogel pillars and microfabrication techniques to create environments that mimic neuron conditions. Reprogramming techniques can enhance myelin regeneration, improving signal transmission and cognitive function in neurodegenerative diseases like multiple sclerosis.

Blood-Brain Barrier

Our blood-brain barrier (BBB) models are essential for studying neurodegenerative diseases. These models replicate the BBB's structure and function, allowing us to investigate interventions that enhance barrier integrity and prevent disease progression. Using advanced microfluidic devices, we mimic the BBB environment, facilitating interactions between brain endothelial cells, pericytes, and astrocytes. By incorporating iPSC-derived astrocytes from familial Alzheimer's disease (fAD) patients, we effectively model BBB dysfunction observed in AD. Our research shows that reprogramming can restore BBB permeability and function, reducing neuroinflammation and providing a platform for screening and treatments.

Great minds, behind great things

Boris Djordjevic

CEO & Founder
Boris is the founder and CEO of 199 Biotechnologies and 199 Clinic, dedicated to translating research in partial reprogramming, gene therapies, and preventive and longevity medicine into clinical products; with a decade of entrepreneurial experience in health and wellness in China, he is now also working on AI and Machine Learning applications for biopharma in the UK.

Emad Moeendarbary

Chief Scientific Officer
Mechanical Engineer and Professor of Mechanobiology at University College London (UCL) and Principal Cancer Research UK Investigator, Emad has made significant strides in cell mechanics during his research at UCL, London Centre for Nanotechnology, University of Cambridge, and Massachusetts Institute of Technology.   His research explores cellular mechanics in ageing, cell biomechanics in the central nervous system, and microfluidic technologies in cancer metastasis. He has a portfolio of publications on high-impact journals such as Nature Communications and Nature Materials.

Emmanuel Ako

Cardiology Medical Officer
Dr Emmanuel Ako, Chief Medical Officer, is a distinguished cardiologist with extensive experience in both clinical and translational medicine. He has served as a Consultant Cardiologist at Royal Brompton & Harefield NHS Foundation Trust and Chelsea and Westminster Hospital. Dr Ako's research has advanced treatments for ischaemic heart disease through innovative stem cell therapies. He has won the American College of Cardiology Young Investigator Award and was a finalist for the SCMR Early Career Awards and the RSM President’s Medal.

Patrick Ellison Sewell Jr.

Chief of Clinical Research and Development
Patrick Ellison Sewell Jr, MD, graduated in 1991 and specialised in Diagnostic, Neuro, Body Interventional, and Vascular Radiology. He pioneered Interventional Oncology and developed image-guided tumour ablation and low-radiation CT software. His innovations were adopted by NASA. Dr Sewell is a leader in stem cell therapies and clinical gene therapy.

Jennifer Brazier

Veterinary Advisor
Jennifer Brazier, with a Masters in Veterinary Epidemiology, is a Named Veterinary Surgeon at the University of Oxford and Senior Veterinary Investigator at the Animal and Plant Health Agency. She directs Brazier Veterinary Consultancy, serves as Treasurer for the Soulsby Foundation, and has extensive experience in animal welfare, regulatory compliance, and data analysis.

Shaif Basier

Finance Advisor
Interim CFO (RA) and Finance Director with 9+ years at Rabobank, Daimler Bank, GE Capital, and Private Equity, specialises in IFRS, Basel, ESG reporting, change management, business control, and financial oversight. He has led strategic financial planning, served as VP Head of Finance at RBS, and chaired the Supervisory Board at Adagio Amsterdam.

Joao Pedro de Magalhaes

Scientific Advisor
Chair of Molecular Biogerontology at the University of Birmingham, leads the Genomics of Ageing and Rejuvenation Lab, focusing on genomic approaches to ageing; he holds a PhD from the University of Namur and completed a postdoc with Prof George Church at Harvard Medical School; with over 100 publications and numerous invited talks, his pioneering research in gene networks and long-lived species genomes aims to develop interventions to improve health and combat age-related diseases.

Aubrey de Grey

Scientific Advisor
Aubrey de Grey: Dr Aubrey de Grey, a biomedical gerontologist and Chief Science Officer of the SENS Research Foundation, holds a PhD from the University of Cambridge and is renowned for his pioneering work on developing therapies to combat the ageing process; he has authored numerous publications and books, given multiple high-profile talks, and his research focuses on the application of regenerative medicine to age-related damage, aiming to significantly extend healthy human lifespan.

We are looking for...

Senior Scientist in Cell Biology

Lead projects focusing on genetics, lipofection, and RNA therapy to advance our aging and regenerative medicine goals. Requires 5+ years of experience with expertise in genetic engineering and cellular reprogramming.

Senior Scientist in Bioinformatics

Develop and apply bioinformatics, ML, and AI tools for analyzing genomic data related to aging and gene therapy. Must have proficiency in Python and R, with 5+ years of relevant experience.

Laboratory Technician

Support research activities by maintaining lab equipment, preparing samples, and conducting experiments. Requires 2+ years of lab experience and knowledge of molecular biology techniques.

Operations Admin

Manage daily administrative tasks, coordinate schedules, and support project logistics. Requires strong organizational skills and experience in office administration.

Machine Learning Scientist

Develop AI models to analyze biological data and optimize therapeutic development. Must have expertise in machine learning algorithms and 3+ years of relevant experience.

Project Manager

Oversee research projects from conception to completion, ensuring timely delivery and adherence to budgets. Requires excellent project management skills and 5+ years of experience in biotech or related fields.

Latest news

Let's talk

Want to learn more? Reach out to us now.
What are you interested in?
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Information:
contact@199.bio
Careers:
careers@199.bio
Investors:
investors@199.bio
Media Inquiries:
media@199.bio